Closed |
S1202 |
Ph III Study of Duloxetine for AI-associated musculoskleteal symptoms for Early Stage BrCa |
5/15/2013 |
10/1/2015 |
100% |
|
Published
|
Closed |
S1222 |
Ph. III Randomized Trial of fulvestrant +/- exemestane +/- everolimus in HR+ postmenopausal Stage IV |
5/9/2014 |
10/15/2015 |
4% |
|
|
Closed |
S1203 |
PIII 7+3 vs IA vs IA+vorinostat for AML |
12/15/2012 |
11/4/2015 |
96% |
|
|
Closed |
S1400A |
Lung-MAP S1400A: Non-Match, MEDI4736 |
6/15/2014 |
11/18/2015 |
83% |
|
|
Closed |
S0905 |
Ph I / Randomized Ph II Mesothelioma Cediranib |
3/15/2010 |
2/15/2016 |
91% |
|
Published
|
Closed |
S1406 |
Rano Ph II of Irino+Cetuximab +/- Vemurafenib in BRAF mutant mCRC |
11/13/2014 |
4/1/2016 |
100% |
|
|
Closed |
S1304 |
RPII Dex + High or Low Dose Carfilzomib for R/R MM |
10/18/2013 |
5/15/2016 |
100% |
|
|
Closed |
S1001 |
Phase II Early Stage DLBCL |
7/18/2011 |
6/1/2016 |
100% |
|
|
Closed |
S1300 |
Rand Ph II of Crizotinib + Pem vs Pem in ALK+ NSCLC Pts Progressing Post Crizotinib |
8/1/2014 |
9/1/2016 |
1% |
|
|
Closed |
S0931 |
Adjuvant Renal Cell, Everolimus vs Placebo, Ph III |
4/1/2011 |
9/15/2016 |
100% |
|
|
Closed |
S1013 |
EGFR Skin Toxicity Validation |
11/15/2011 |
10/1/2016 |
94% |
|
|
Closed |
S1400D |
Lung-MAP S1400D: FGFR - AZD4547 |
6/15/2014 |
10/31/2016 |
81% |
|
|
Closed |
S1400B |
Lung-MAP S1400B: PI3K - GDC-0032 |
6/15/2014 |
12/12/2016 |
57% |
|
|
Closed |
S1204 |
Viral Screening Study |
8/29/2013 |
2/15/2017 |
100% |
|
|
Closed |
S1011 |
Muscle-Invasive Bladder Ca, Std vs Ext PLND, Ph III |
8/1/2011 |
4/15/2017 |
100% |
|
|
Closed |
S1216 |
Metastatic Prostate Cancer, Phase III ADT+TAK-700 vs. ADT+Bicalutamide |
3/1/2013 |
7/15/2017 |
100% |
|
|
Closed |
S0919 |
Phase II Idarubicin/AraC + Pravastatin for Relapsed AML |
8/15/2009 |
9/15/2017 |
100% |
|
|
Closed |
S1314 |
Phase II COXEN Trial for Localized Bladder Cancer |
7/9/2014 |
12/1/2017 |
100% |
|
|
Closed |
S1507 |
Ph II Tram + doce with kras NSCLC + and PD |
7/18/2016 |
3/15/2018 |
100% |
|
|
Closed |
S1403 |
Lung Ph II/III Stage IV NSCLC Afatinib+Cetuximab vs Afatinib |
3/25/2015 |
4/23/2018 |
29% |
|
|